0.8542
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CTXR Technical Analysis & Stock Price Forecast - Intellectia AI
Breakouts Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Risk Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology highlights early LYMPHIR commercial traction, expansion - tipranks.com
Citius Oncology advances LYMPHIR launch and global expansion - tipranks.com
Bond Watch: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Performance Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development - Finviz
Citius Pharmaceuticals subsidiary reports strong early uptake and broad payer coverage for LYMPHIR launch - TradingView
Citius Oncology (CTXR) details early LYMPHIR launch uptake and $400M CTCL market - Stock Titan
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - ChartMill
Citius Pharmaceuticals Inc (47N0.MU) balance sheet - Yahoo Finance UK
RSI Check: Is Citius Pharmaceuticals Inc stock good for income investors2026 Sector Review & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Citius Pharmaceuticals Inc (47N0.MU) recent insider transactions - Yahoo Finance UK
Rate Hike: Is Citius Pharmaceuticals Inc a cyclical or defensive stock2026 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals to present CTCL clinical experience at USCLC Annual Workshop - tradersunion.com
Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts - Finviz
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Nasdaq
Aug Mood: Can Citius Pharmaceuticals Inc withstand a market correctionEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
Downgrade Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Macro Review: Should I buy Citius Pharmaceuticals Inc stock nowSell Signal & Growth Oriented Trading Recommendations - baoquankhu1.vn
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Ideas Watch: Is Euroholdings Ltd stock trending bullishEarnings Recap Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Energy Moves: Does Citius Pharmaceuticals Inc align with a passive investing strategyMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
D Boral Capital maintains Citius Pharmaceuticals (CTXR) buy recommendation - MSN
Activity Recap: Is Citius Pharmaceuticals Inc a potential multi baggerIPO Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Activity Recap: Is Citius Pharmaceuticals Inc stock good for income investors2026 Historical Comparison & AI Forecast Swing Trade Picks - baoquankhu1.vn
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - ca.investing.com
Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - Finviz
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - BioSpace
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com
LYMPHIR combo shows activity in gynecologic cancers for Citius (CTXR) - Stock Titan
Market Review: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Bull Bear: Is Citius Pharmaceuticals Inc in a long term uptrendPortfolio Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance
33 Stocks That Should Double in 3 Years - Insider Monkey
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - BioSpace
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Phase 1 LYMPHIR data in high-risk DLBCL for Citius Oncology (Nasdaq: CTOR) - Stock Titan
Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
CTXR Should I Buy - Intellectia AI
Citius Pharmaceuticals CEO Leonard Mazur pursues growth through regulatory partnerships and rare disease therapies - Traders Union
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
CTXR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Movement Recap: Is Citius Pharmaceuticals Inc benefiting from interest rate changesJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Citius Pharmaceuticals Secures $3.8M Via Net Operating Loss Program - New Jersey Business Magazine
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):